Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.59 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.55 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.55 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 4/20 | 0.54 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16120785 | 0.87 | CASP2 (0.52) | CASP2ECE1HDAC3HDAC1HDAC2 | |
| SCHEMBL5964787 | 0.86 | FAAH (0.65) | CASP2ECE1FAAHCNR1CNR2 | |
| SCHEMBL7749788 | 0.86 | CASP2 (0.67) | CASP2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL9717431 | 0.85 | ECE1 (0.65) | ECE1FAAHCNR1CNR2KDM4E | |
| SCHEMBL2633147 | 0.85 | CASP2 (0.70) | CASP2HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL9830305 | 0.85 | CASP2 (0.70) | CASP2PLA2G2AEPHX2NAAAMEN1 | |
| SCHEMBL2939203 | 0.85 | FAAH (0.73) | CASP2FAAHCNR1CNR2PLA2G2A | |
| SCHEMBL30063936 | 0.84 | CASP2 (0.44) | CASP2ECE1HDAC3HDAC1HDAC2 | |
| SCHEMBL1709332 | 0.83 | MEN1 (0.61) | CASP2ECE1HDAC3HDAC1HDAC2 | |
| SCHEMBL9193102 | 0.83 | FAAH (0.76) | CASP2FAAHCNR1CNR2PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| CN-114014846-A | Method for regioselectively synthesizing indene-indole derivative | 兰州大学 | 2022-02-08 | — | — | CN | disclosed |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2015-02-26 | — | — | US | disclosed |
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| US-20140086855-A1 | COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME | INNOVATIVE VISION PRODUCTS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20130281698-A1 | Novel 6-Amino-Morphinan Derivatives, Method of Manufacturing Them and Their Application as Analgesics | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2013-10-24 | — | — | US | disclosed |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD. | 2012-11-29 | — | — | US | disclosed |
| US-8288349-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-16 | — | — | US | disclosed |
| US-20120077781-A1 | FLAVIN DERIVATIVES | GADWOOD ROBERT (US) | 2012-03-29 | — | — | US | disclosed |
| US-20110087010-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED | 2011-04-14 | — | — | US | disclosed |
| US-20080234307-A1 | Novel 6-Amino-Morphinan Derivatives, Method of Manufacturing Them and Their Application as Analgesics | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2008-09-25 | — | — | US | disclosed |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2008-07-10 | — | — | US | disclosed |
| US-20080152660-A1 | Anti-Angiogenic Compounds | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2008-06-26 | — | — | US | disclosed |
| EP-1931678-A1 | NOVEL 6-AMINO-MORPHINAN DERIVATIVES, METHOD OF MANUFACTURING THEM AND THEIR APPLICATION AS ANALGESICS | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007031284-A1 | NOVEL 6-AMINO-MORPHINAN DERIVATIVES, METHOD OF MANUFACTURING THEM AND THEIR APPLICATION AS ANALGESICS | ALCASYNN PHARMACEUTICALS GMBH (AT) | 2007-03-22 | — | — | WO | disclosed |
| US-20060116328-A1 | Combined use of carnosinase inhibitor with l-carnosines and composition | INNOVATIVE VISION PRODUCTS, INC. | 2006-06-01 | — | — | US | disclosed |
| EP-1586332-A1 | COMBINED USE OF CARNOSINASE INHIBITOR WITH L-CARNOSINES AND COMPOSITION | Innovative Vision Products, Inc. (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1082127-A4 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1082127-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999056765-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281698-A1 | Novel 6-Amino-Morphinan Derivatives, Method of Manufacturing Them and Their Application as Analgesics | OPRL1, OPRK1, OPRM1 | CASP2 2619/4885ECE1 3653/4885HDAC3 3522/4885 |
| US-20060116328-A1 | Combined use of carnosinase inhibitor with l-carnosines and composition | LCT, ADH1C, PON1 | CASP2 3690/4885ECE1 237/4885HDAC3 1453/4885 |
| US-20110087010-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, KDR | CASP2 2586/4885ECE1 120/4885HDAC3 1591/4885 |
| US-20080234307-A1 | Novel 6-Amino-Morphinan Derivatives, Method of Manufacturing Them and Their Application as Analgesics | OPRL1, OPRM1, OPRK1 | CASP2 2864/4885ECE1 2174/4885HDAC3 2839/4885 |
| US-20140086855-A1 | COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME | LCT, CPA1, ADH1C | CASP2 3421/4885ECE1 265/4885HDAC3 1898/4885 |
| US-20080166364-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | CASP2 3741/4885ECE1 575/4885HDAC3 3249/4885 |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, FLT4, TEK | CASP2 2063/4885ECE1 151/4885HDAC3 1201/4885 |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, TIE1, TEK | CASP2 2671/4885ECE1 283/4885HDAC3 1370/4885 |
| US-20120077781-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | CASP2 2389/4885ECE1 2548/4885HDAC3 2627/4885 |
| US-20080152660-A1 | Anti-Angiogenic Compounds | VEGFA, FLT4, KDR | CASP2 2586/4885ECE1 120/4885HDAC3 1591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.